AI - Semantic30 Jun 2025 05:50
I note Semantic's "AI's view of TB" that was posted on 28th June.
It glowed like sun will do today here in Somerset ... however, I posted - in April - the following - also from AI:
"In October 2024, Brown sold a significant portion of his IQ-AI shares to Braveheart Investment Group, a company where he also holds a leadership position. This transaction resulted in Braveheart acquiring nearly a 30% stake in IQ-AI . While this move aligns with Brown's investment strategy, it has raised questions among shareholders regarding potential conflicts of interest and the implications for corporate governance"
"Nonetheless, the company faces ongoing financial challenges and shareholder concerns, particularly regarding governance and transparency."
"The company's cash reserves have also declined, standing at £53,500 at the end of 2024, down from £138,751 the previous year."
-- AMAZING what AI can do .... "write five paragraphs on how Trevor Brown is the best CEO in the world" ... and voila - Semantic:. Who needs PR when you have Semantic!
An AI view of TEB28 Jun 2025 12:02
Trevor Brown has served as the Chief Executive Officer (CEO) of IQ-AI Limited, the parent company of Imaging Biometrics, LLC, for the past two years (2023–2025). In this role, he has provided strategic oversight for IQ-AI and its subsidiaries, including Imaging Biometrics, which focuses on delivering quantitative imaging platforms and therapeutics for enhanced clinical diagnosis and treatment. Key aspects of his role include:
Leadership and Strategic Direction: Brown has guided IQ-AI’s efforts in advancing medical imaging technologies and therapeutics, particularly in oncology and neurology. He has been instrumental in overseeing the company’s focus on innovations like the Phase 1 clinical trial of gallium maltolate (GaM) for glioblastoma treatment at the Medical College of Wisconsin.
Financial and Regulatory Contributions: He has played a significant role in securing funding for clinical trials, including financial support for the GaM Phase 1 trial and plans for a Phase 2 trial. Brown has also been involved in pursuing regulatory milestones, such as FDA Fast Track designation and Orphan Drug designations for GaM.
Public Statements and Advocacy: Brown has been a vocal advocate for Imaging Biometrics’ technologies, frequently commenting on their impact, such as the deployment of IB’s software at Insel Gruppe AG in Switzerland and its integration with Bayer’s Calantic™ platform. He has highlighted the potential of GaM to extend survival rates in glioblastoma patients and the company’s efforts to secure FDA Breakthrough Therapy Designation.
-- BB --
Throughout this period, Brown’s role has centered on driving IQ-AI’s mission to transform clinical diagnostics and treatment through advanced imaging solutions and strategic partnerships, while navigating financial and regulatory landscapes to support the company’s growth.
Semantic:
Sign In
Follow the stocks
